Shattuck Labs, Inc. Sale of Stock, Consideration Received on Transaction
Shattuck Labs, Inc. (STTK) reported Sale of Stock, Consideration Received on Transaction of $117.00 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2021-11-09.
Discontinued › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2021-11-09
- Shattuck Labs, Inc. sale of stock, consideration received on transaction for the quarter ending 2020-09-30 was $0.00.
| Period end | Sale of Stock, Consideration Received on Transaction 3 month | Sale of Stock, Consideration Received on Transaction 6 month | Sale of Stock, Consideration Received on Transaction 9 month |
|---|---|---|---|
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $117.00M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $117.00M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |